HumanInsight Remote decentralized clinical trials: a new opportunity for laboratory medicine
Clin Chem Lab Med. 2023 Jan 5. doi: 10.1515/cclm-2022-1184. Online ahead of print.
The traditional venue of clinical trials has been hospitals or specialized research units, usually requiring participants to come on-site. Although their contribution to biomedical progress is beyond dispute, they are characterised by two crucial logistical and ultimately scientifical limitations: poor retention and poor generalizability of results, as patients often have problems in concluding the investigation on-site. Remote Decentralised Clinical Trials (RDCTs) take advantage of digital technologies to design trial activities closer to the home of participants, with the aims of minimizing travel to health facilities and the risk of infections, improving the quality of life of participants and caregivers, reducing work absenteeism, including broader cohorts of patients and possibly reducing costs. RDCTs represent a minority of current global research, but the Covid-19 pandemic brought them to the fore. The authors of this paper promote the spread of RDCTs, building on early recommendations from international institutions, and provide some examples of their use and potential benefits in laboratory medicine.
PMID:36597971 | DOI:10.1515/cclm-2022-1184
Powered by WPeMatico
Viale Campi Flegrei 55
80124 - Napoli
Via G.Porzio 4
Centro Direzionale G1
80143 - Napoli